Novartis

Granite Bio is a biotechnology company focused on developing novel monoclonal antibodies aimed at treating inflammatory, autoimmune, and fibrotic disorders. The company specializes in creating therapeutic antibodies that deplete pathogenic cells and selectively target key biological processes associated with these diseases. By concentrating on these advanced treatments, Granite Bio contributes to the broader fields of biotechnology, pharmaceuticals, and diagnostics, ultimately seeking to improve patient outcomes in complex medical conditions.

Mariana Oncology is a biotechnology company focused on developing radiopharmaceuticals designed to target cancer cells using radioactive drugs. The company leverages expertise in ligand discovery, radiochemistry, and radiobiology, along with oncology translational and clinical research, to create a diverse pipeline aimed at treating various solid tumor types. By advancing the use of radiomedicines, Mariana Oncology seeks to enhance treatment options for medical professionals in their fight against cancer.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.

Patientory, Inc. is a healthcare technology company based in Atlanta, Georgia, established in 2015. It offers a health data management platform that enables individuals to securely store, manage, and share their health information. The platform empowers patients to take control of their medical records and chronic illness management while facilitating better communication and support between healthcare providers and patients. By integrating a blockchain-enabled network, Patientory streamlines access to health data, enhances care coordination, and provides insights into health outcomes. This approach aims to democratize health data ownership, reduce healthcare costs, and improve overall patient engagement and health management.

Klarah is a digital health company specializing in telehealth solutions. It offers a network of specialist doctors and nurses for remote consultations and patient support. The platform provides a dashboard for accessing medical history and real-time health updates. Services include wound care, wellness checks, post-hospital care, and diabetes management, primarily catering to individuals seeking healthcare for loved ones in Africa.

GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs technologies. This innovative approach is designed to restore immune tolerance and address limitations present in current regulatory T-cell therapies. By targeting the underlying causes of diseases related to immune system dysfunction, GentiBio aims to provide effective therapeutic solutions for conditions that arise from immune system overshooting or malfunctioning. The company was co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of this emerging field.

Aspen RxHealth is a Tampa, Florida-based company that provides an online platform designed to connect licensed pharmacists with patients requiring enhanced medication services. Through its app-based technology, Aspen RxHealth facilitates direct patient care by matching pharmacists to patients based on various social and clinical criteria, such as language and medication regimens. This platform enables health plans and providers to link their patients with a community of pharmacists who can deliver clinical services tailored to individual needs. The services offered include comprehensive medication reviews and targeted medication interventions, all aimed at optimizing communication and improving patient care.

GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs technologies. This innovative approach is designed to restore immune tolerance and address limitations present in current regulatory T-cell therapies. By targeting the underlying causes of diseases related to immune system dysfunction, GentiBio aims to provide effective therapeutic solutions for conditions that arise from immune system overshooting or malfunctioning. The company was co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of this emerging field.

Poseida Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company utilizes non-viral gene engineering technologies to create a pipeline of targeted therapies, including both autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates aimed at treating hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency, methylmalonic acidemia, and various genetic liver diseases. Founded in 2014, Poseida is committed to addressing critical health challenges through its focused research and development efforts.

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

Lemonaid Health is an online telemedicine platform founded in 2013 and headquartered in San Francisco, California. The company aims to enhance the patient experience and optimize clinical care by utilizing advancements in machine learning and artificial intelligence. By collecting details about medical history, symptoms, current medications, and allergies, Lemonaid Health employs evidence-based guidelines to provide patients with prescriptions. This approach allows users to access quality healthcare services at a price point lower than typical co-pays, making healthcare more affordable and accessible.

Inflazome Ltd. is a biotechnology company based in Dublin, Ireland, founded in 2016. It specializes in developing orally available drugs aimed at addressing unmet clinical needs in inflammatory diseases by targeting the inflammasome, a component involved in the inflammatory process. The company’s innovative therapies are designed to block inflammasome signals, effectively tackling various inflammatory-driven conditions. These include orphan diseases, central nervous system disorders such as Alzheimer's and Parkinson's, systemic inflammatory diseases like cardiovascular and pulmonary conditions, and applications in ophthalmology and dermatology. By targeting the root causes of inflammation, Inflazome enables the development of precise treatments for a range of diseases, thereby enhancing therapeutic options for healthcare providers. As of September 2020, Inflazome operates as a subsidiary of Roche Holding AG.

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.

Alios BioPharma is focused on the discovery and development of innovative antiviral therapies aimed at treating both acute and chronic viral infections. The company employs a range of proprietary technologies, including small molecule activators that stimulate innate immunity, phosphate-protected nucleotide prodrug chemistry, and glycoprotein engineering of interferons. These complementary platforms enable the development of various therapeutic products targeting serious viral infections, such as chronic hepatitis B and C, HIV, respiratory viruses like pandemic influenza, and emerging viral diseases such as SARS. Alios BioPharma’s unique chemical library of nucleoside analogs and advanced virology-based screening systems further enhance its ability to create effective antiviral agents.

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.

Forma Therapeutics, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in developing and commercializing novel therapeutics for rare hematologic diseases and cancers. Its pipeline includes FT-4202 in Phase 1 trials for sickle cell disease, FT-7051 for metastatic castration-resistant prostate cancer, FT-2102 in Phase 2 trials for relapsed/refractory AML and exploratory Phase 1 trials for glioma, and selective fatty acid synthase inhibitors FT-4101 and FT-8225. Forma's approach integrates innovative drug discovery technologies and oncology expertise to target high-value, challenging drug targets validated through genomic medicine.

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, focused on developing innovative inhaled therapies for serious pulmonary diseases. Utilizing its proprietary iSPERSE technology, which stands for inhaled Small Particles Easily Respirable and Emitted, Pulmatrix aims to enhance the delivery of therapeutic agents directly to the lungs while minimizing systemic side effects. The company's product pipeline includes Pulmazole, an inhaled anti-fungal targeting allergic bronchopulmonary aspergillosis, and PUR1800, a narrow spectrum kinase inhibitor designed for obstructive lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). Established in 2003, Pulmatrix collaborates with various partners, including RespiVert Ltd. and Cipla Technologies LLC, to advance its drug candidates and address significant unmet medical needs in respiratory care.

Forma Therapeutics, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in developing and commercializing novel therapeutics for rare hematologic diseases and cancers. Its pipeline includes FT-4202 in Phase 1 trials for sickle cell disease, FT-7051 for metastatic castration-resistant prostate cancer, FT-2102 in Phase 2 trials for relapsed/refractory AML and exploratory Phase 1 trials for glioma, and selective fatty acid synthase inhibitors FT-4101 and FT-8225. Forma's approach integrates innovative drug discovery technologies and oncology expertise to target high-value, challenging drug targets validated through genomic medicine.

Forma Therapeutics, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in developing and commercializing novel therapeutics for rare hematologic diseases and cancers. Its pipeline includes FT-4202 in Phase 1 trials for sickle cell disease, FT-7051 for metastatic castration-resistant prostate cancer, FT-2102 in Phase 2 trials for relapsed/refractory AML and exploratory Phase 1 trials for glioma, and selective fatty acid synthase inhibitors FT-4101 and FT-8225. Forma's approach integrates innovative drug discovery technologies and oncology expertise to target high-value, challenging drug targets validated through genomic medicine.

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, focused on developing innovative inhaled therapies for serious pulmonary diseases. Utilizing its proprietary iSPERSE technology, which stands for inhaled Small Particles Easily Respirable and Emitted, Pulmatrix aims to enhance the delivery of therapeutic agents directly to the lungs while minimizing systemic side effects. The company's product pipeline includes Pulmazole, an inhaled anti-fungal targeting allergic bronchopulmonary aspergillosis, and PUR1800, a narrow spectrum kinase inhibitor designed for obstructive lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). Established in 2003, Pulmatrix collaborates with various partners, including RespiVert Ltd. and Cipla Technologies LLC, to advance its drug candidates and address significant unmet medical needs in respiratory care.

Alios BioPharma is focused on the discovery and development of innovative antiviral therapies aimed at treating both acute and chronic viral infections. The company employs a range of proprietary technologies, including small molecule activators that stimulate innate immunity, phosphate-protected nucleotide prodrug chemistry, and glycoprotein engineering of interferons. These complementary platforms enable the development of various therapeutic products targeting serious viral infections, such as chronic hepatitis B and C, HIV, respiratory viruses like pandemic influenza, and emerging viral diseases such as SARS. Alios BioPharma’s unique chemical library of nucleoside analogs and advanced virology-based screening systems further enhance its ability to create effective antiviral agents.

Alios BioPharma is focused on the discovery and development of innovative antiviral therapies aimed at treating both acute and chronic viral infections. The company employs a range of proprietary technologies, including small molecule activators that stimulate innate immunity, phosphate-protected nucleotide prodrug chemistry, and glycoprotein engineering of interferons. These complementary platforms enable the development of various therapeutic products targeting serious viral infections, such as chronic hepatitis B and C, HIV, respiratory viruses like pandemic influenza, and emerging viral diseases such as SARS. Alios BioPharma’s unique chemical library of nucleoside analogs and advanced virology-based screening systems further enhance its ability to create effective antiviral agents.

Intradigm is a private biotechnology company focused on developing systematic RNA interference (RNAi) therapeutics aimed at treating serious diseases, with an initial emphasis on oncology. The company leverages its expertise in drug development and delivery to create a proprietary RNAi platform, which includes unique RNAi Nanoplex delivery technology. This technology enables the targeted delivery of RNAi therapeutics to specific tissues through systemic administration. Intradigm's portfolio encompasses RNAi molecules, biodegradable polycationic polymers for therapeutic delivery, and a range of siRNA sequences targeting various oncology and other disease-related applications.

Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert Rüf Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as well as its high sensitivity and specificity.

Forma Therapeutics, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in developing and commercializing novel therapeutics for rare hematologic diseases and cancers. Its pipeline includes FT-4202 in Phase 1 trials for sickle cell disease, FT-7051 for metastatic castration-resistant prostate cancer, FT-2102 in Phase 2 trials for relapsed/refractory AML and exploratory Phase 1 trials for glioma, and selective fatty acid synthase inhibitors FT-4101 and FT-8225. Forma's approach integrates innovative drug discovery technologies and oncology expertise to target high-value, challenging drug targets validated through genomic medicine.

Intradigm is a private biotechnology company focused on developing systematic RNA interference (RNAi) therapeutics aimed at treating serious diseases, with an initial emphasis on oncology. The company leverages its expertise in drug development and delivery to create a proprietary RNAi platform, which includes unique RNAi Nanoplex delivery technology. This technology enables the targeted delivery of RNAi therapeutics to specific tissues through systemic administration. Intradigm's portfolio encompasses RNAi molecules, biodegradable polycationic polymers for therapeutic delivery, and a range of siRNA sequences targeting various oncology and other disease-related applications.

Lumenos is a healthcare company that provides a range of healthcare plans and support services. It offers health accounts, including Health Reimbursement Accounts and Health Savings Accounts, as well as information and incentives aimed at promoting health awareness and engagement in healthy behaviors. The company operates a website that features various health and financial tools, along with a directory of doctors and hospitals. Additionally, Lumenos provides personal health coaching services, offering one-on-one assistance to patients managing chronic conditions such as asthma, diabetes, and heart disease.

Lumenos is a healthcare company that provides a range of healthcare plans and support services. It offers health accounts, including Health Reimbursement Accounts and Health Savings Accounts, as well as information and incentives aimed at promoting health awareness and engagement in healthy behaviors. The company operates a website that features various health and financial tools, along with a directory of doctors and hospitals. Additionally, Lumenos provides personal health coaching services, offering one-on-one assistance to patients managing chronic conditions such as asthma, diabetes, and heart disease.